Literature DB >> 2549723

Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers.

T Matsukura1, S Koi, M Sugase.   

Abstract

The form of human papillomavirus type 16 (HPV 16)DNA in specimens of invasive cervical cancer was investigated. High molecular, tandem repeats of viral sequences were detected as several distinct bands, using a low concentration (0.5%) agarose gel and a no-cut enzyme (HindIII) for HPV 16. Two-dimensional agarose gel electrophoresis allowed us to differentiate between the episomal multimeric and the integrated forms of viral DNA. All 34 cervical cancer specimens showed the characteristic PstI cleavage pattern of HPV 16 DNA, indicating that a full viral genome was present in these specimens, and 24 specimens (70%) showed only episomal monomeric or multimeric forms without the integrated form of HPV 16 DNA. The remaining 10 specimens (30%) showed integrated multimeric forms of viral DNA, either without the episomal form (8 specimens) or with the concomitant episomal form (2 specimens). In addition, a metastatic tumor in a pelvic lymph node showed only the episomal form of viral DNA, whereas its primary cervical cancer showed both episomal and integrated forms of viral DNA. There was no correlation between the forms of viral DNA and the clinical stages of tumors. The result indicates that both episomal and integrated forms of a complete HPV 16 DNA are involved in invasive cervical cancers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2549723     DOI: 10.1016/0042-6822(89)90107-4

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  37 in total

Review 1.  Laboratory techniques in the investigation of human papillomavirus infection.

Authors:  E M de Villiers
Journal:  Genitourin Med       Date:  1992-02

2.  The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification.

Authors:  Frank A Suprynowicz; Ewa Krawczyk; Jess D Hebert; Sawali R Sudarshan; Vera Simic; Christopher M Kamonjoh; Richard Schlegel
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

3.  E5 can be expressed in anal cancer and leads to epidermal growth factor receptor-induced invasion in a human papillomavirus 16-transformed anal epithelial cell line.

Authors:  Erin Isaacson Wechsler; Sharof Tugizov; Rossana Herrera; Maria Da Costa; Joel M Palefsky
Journal:  J Gen Virol       Date:  2018-04-06       Impact factor: 3.891

4.  CpG methylation directly inhibits binding of the human papillomavirus type 16 E2 protein to specific DNA sequences.

Authors:  A Thain; O Jenkins; A R Clarke; K Gaston
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

5.  Suppression in vivo of human papillomavirus type 18 E6-E7 gene expression in nontumorigenic HeLa X fibroblast hybrid cells.

Authors:  F X Bosch; E Schwarz; P Boukamp; N E Fusenig; D Bartsch; H zur Hausen
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

Review 6.  Human papillomavirus molecular biology.

Authors:  Mallory E Harden; Karl Munger
Journal:  Mutat Res Rev Mutat Res       Date:  2016-07-05       Impact factor: 5.657

7.  Small tumor virus genomes are integrated near nuclear matrix attachment regions in transformed cells.

Authors:  K A Shera; C A Shera; J K McDougall
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

8.  Analysis of HPV16, 18, 31, and 35 DNA in pre-invasive and invasive lesions of the uterine cervix.

Authors:  L Pirami; V Giachè; A Becciolini
Journal:  J Clin Pathol       Date:  1997-07       Impact factor: 3.411

9.  The integration of HPV-18 DNA in cervical carcinoma.

Authors:  S A Corden; L J Sant-Cassia; A J Easton; A G Morris
Journal:  Mol Pathol       Date:  1999-10

10.  Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm.

Authors:  A P Cullen; R Reid; M Campion; A T Lörincz
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.